HBV Drug Resistance

### HBV Drug Resistance: A Simple Overview

Hepatitis B Virus (HBV) drug resistance happens when the virus develops changes (mutations) in its DNA that make antiviral medications less effective. This is a serious issue in managing chronic hepatitis B (CHB) because it can lead to treatment failure, worsening liver disease, and complications like liver damage and decompensation.

---

### **How Does HBV Drug Resistance Occur?**

1. **Primary Mutations**:

• These are changes in the HBV DNA polymerase (enzyme) that directly make the virus resistant to drugs.
• Example: **YMDD motif mutation (rtM204V/I)** causes resistance to lamivudine.

2. **Secondary (Compensatory) Mutations**:

• These mutations help the virus regain its ability to replicate even in the presence of drugs.
• Example: **rtL180M** often pairs with rtM204V/I to improve the virus’s replication in lamivudine-resistant cases.

3. **Cross-Resistance**:

• Some mutations make the virus resistant to multiple drugs in the same class.
• Example: Lamivudine resistance mutations (rtM204V/I) also affect telbivudine and entecavir.

---

### **Common Drug Resistance Mutations**

| **Drug** | **Key Mutations** | **Resistance Rate** | **Cross-Resistance** | **Management Options** |

|-----------------------|---------------------------|---------------------|----------------------------------|-------------------------------------|

| **Lamivudine** | rtM204V/I, rtL180M | High (75% at 4 years) | Telbivudine, entecavir | Switch to Tenofovir (TDF/TAF) |

| **Adefovir** | rtA181T/V, rtN236T | Moderate (29% at 5 years) | Partial resistance to TDF | Switch to TDF/TAF |

| **Telbivudine** | rtM204I | High (22% at 2 years) | Lamivudine, entecavir | Switch to TDF/TAF |

| **Entecavir** | rtL180M + rtM204V + rtS202I/rtM250V | Rare in new patients; common in lamivudine-experienced patients | None | Switch to TDF/TAF |

| **Tenofovir (TDF/TAF)** | rtA194T | Rare (<1% at 5 years) | None | No resistance reported in CHB |

---

### **Why Is Drug Resistance a Problem?**

1. **Virological Breakthrough**:

• HBV DNA levels increase during treatment, meaning the virus is no longer controlled.

2. **Liver Damage (ALT Flares)**:

• Resistance can cause inflammation in the liver, leading to elevated ALT levels (a marker of liver injury). This may cause liver failure in severe cases.

3. **Multidrug Resistance**:

• Using drugs with overlapping resistance profiles (e.g., lamivudine followed by entecavir) can lead to strains of HBV resistant to multiple treatments.

---

### **How Is HBV Drug Resistance Diagnosed?**

1. **Monitoring HBV DNA Levels**:

• Regular blood tests to check if HBV DNA levels increase during treatment. A rise of ≥1 log IU/mL suggests resistance.

2. **Genotypic Testing**:

• Identifies specific mutations in the HBV polymerase gene using techniques like sequencing or hybridization assays.

3. **Phenotypic Testing**:

• Checks how the mutations affect drug effectiveness.

---

### **How Is HBV Drug Resistance Managed?**

1. **Switch to High-Barrier Drugs**:

• Use medications with low resistance rates, like **Tenofovir (TDF/TAF)** or **Entecavir**.
• Example: If lamivudine resistance occurs, switch to TDF or TAF.

2. **Combination Therapy**:

• In complex cases of multidrug resistance, combining TDF and entecavir may be effective.

3. **Early Intervention**:

• Act quickly when resistance is detected to prevent further mutations.

4. **Avoid Sequential Monotherapy**:

• Avoid using drugs with overlapping resistance profiles one after the other.

5. **Ensure Patient Compliance**:

• Regularly check that patients are taking medications correctly to reduce the risk of resistance.

---

### **Preventing HBV Drug Resistance**

1. **Use High-Barrier Agents**:

• Start treatment with drugs like **Tenofovir (TDF/TAF)** or **Entecavir**, which have very low resistance rates.

2. **Monitor Regularly**:

• Check HBV DNA levels frequently to catch resistance early.

3. **Avoid Overlapping Resistance Drugs**:

• Be careful when switching treatments to avoid cross-resistance.

4. **Combination Therapy**:

• In some cases, combining drugs upfront may help prevent resistance.

---

### **Key Takeaways**

• **Lamivudine Resistance**: Most common, caused by YMDD motif mutations (rtM204V/I).
• **Preferred Drugs**: Tenofovir (TDF/TAF) and entecavir are the best options due to their low resistance rates.
• **Detection**: Regular HBV DNA testing and genotypic testing are essential.
• **Management**: Switch to non-cross-resistant drugs or combine treatments for multidrug resistance.
• **Prevention**: Start with high-barrier drugs, monitor closely, and ensure compliance.

By understanding HBV drug resistance, doctors can choose better treatments and improve outcomes for patients with chronic hepatitis B.